Pharmaceutical care in the screening process of phase I oncohaematological clinical trials.

Autor:	Rodríguez-Mauriz R; Pharmacy Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain rosarmauriz@gmail.com., González-Laguna M; Pharmacy Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain., Perayre-Badia M; Pharmacy Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain., Lozano-Andreu T; Pharmacy Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain., Miquel-Zurita ME; Pharmacy Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain., Cañizares-Paz S; Pharmacy Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain., Santulario-Verdú L; Pharmacy Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain., Millan-Coll M; Pharmacy Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain., Fontanals S; Pharmacy Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain.; Instituto de Investigación Biomédica de Bellvitge, Barcelona, Spain., Clopés-Estela A; Pharmacy Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain.; Instituto de Investigación Biomédica de Bellvitge, Barcelona, Spain.
Jazyk:	angličtina
Zdroj:	European journal of hospital pharmacy : science and practice [Eur J Hosp Pharm] 2024 Aug 13. Date of Electronic Publication: 2024 Aug 13.
DOI:	10.1136/ejhpharm-2024-004168
Abstrakt:	Objective: To determine the pharmaceutical interventions in patients eligible for phase I cancer clinical trials, focusing specifically on exclusion criteria related to medication or relevant interactions. Method: Descriptive, observational study conducted at a comprehensive cancer centre. Patients undergoing screening for phase I clinical trials (March 2019-December 2022) were included. The pharmacist reviewed concomitant medication and provided a recommendation. Results: The concomitant medication of 512 patients eligible to participate in 84 phase I clinical trials was analysed. In 230 (44.9%) patients, the clinical trial treatment included oral medication. The median number of concomitant medications was 5 (IQR 3-8) per patient.A total of 280 pharmaceutical interventions were performed in 140 (27.3%) patients: 240 (85.7%) were due to interactions in 124 (24.2%) patients, and 40 (14.3%) were due to exclusion criteria in 34 (6.6%) patients. Interactions and exclusion criteria were detected in 18 (3.5%) patients. The main groups of drugs involved were 68 (24.3%) antacids and antiulcer drugs, 28 (10.0%) antidepressants and 26 (9.3%) opioids. Acceptance analysis of the recommendation was applicable in 215 cases; in 208 (96.7%), the pharmaceutical intervention was accepted.Differences were identified for exclusion criteria (7 vs 27) and interactions (37 vs 87) between parenteral and oral clinical trial medication (p<0.001). Conclusion: The pharmacist's review of concomitant medication during the screening period in phase I clinical trials enables the detection of prohibited medication or relevant interactions, potentially avoiding screening failures and increasing the efficacy and safety of treatments. Competing Interests: Competing interests: None declared. (© European Association of Hospital Pharmacists 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu